protein bound. Multiple cytochrome P450 enzymes extensively metabolize nabilone to various metabolites that have not been fully characterized. Chemistry Nabilone is a racemic mixture consisting of (S,S)-(+)- and (R,R)-(−)-isomers. History Nabilone was originally developed by Eli Lilly and Company; Lilly received FDA approval in 1985 to market it, but withdrew that approval in 1989 for commercial reasons. Valeant Pharmaceuticals acquired the rights from Lilly in 2004. Valeant tried and failed to get the medication approved in 2005 and then succeeded in 2006. In 2007, Valeant acquired the United Kingdom and European Union rights to market nabilone from Cambridge Laboratories. Nabilone was approved in Austria to treat chemotherapy-induced nausea in 2013; it was already approved in Spain for the same indication and was legal in Belgium to treat glaucoma, spasticity in multiple sclerosis, wasting due to AIDS, and chronic pain. See also List of investigational analgesics References Analgesics Appetite stimulants Benzochromenes Cannabinoids Ketones Phenols